-
The National Talks on the Five Limits of Anticancer Drugs is here!
Time of Update: 2021-08-28
Participating patients purchase nationally negotiated anticancer drugs at designated retail pharmacies with prescriptions, and enjoy medical insurance benefits in accordance with the relevant provisions of the city’s outpatient clinics for specific diseases .
-
Shanxi and Sichuan provinces publicly solicit opinions on the implementation rules for post-marketing drug changes
Time of Update: 2021-08-28
On August 12, the Shanxi Provincial Drug Administration released its opinions on the "Implementation Rules for the Administration of Post-Market Modification Recording (Trial)" (Draft for Solicitation
-
How to overcome the difficulties in the industry when the signal of centralized procurement of Chinese patent medicines is transmitted?
Time of Update: 2021-08-28
" On the basis of this, we adhere to the principle of giving priority to quality, being clinically demand-oriented, starting with high-priced and large-volume varieties, and scientifically and steadily advancing the reform of centralized procurement of proprietary Chinese medicines and formula granules .
-
Fosun Pharma Holding Subsidiary's Trastuzumab for Injection Obtained Notice of Approval of Supplementary Drug Application
Time of Update: 2021-08-28
On August 17, Fosun Pharma issued an announcement stating that its controlling subsidiary Hanlius Pharmaceuticals had received the "Drug Supplementary Application for Trastuzumab for Injection (trade name: Hanquyou®) issued by the National Medical Products Administration.
-
A list of 17 groups of products will be announced soon
Time of Update: 2021-08-28
In order to further expand the scale of centralized procurement, and take advantage of the linkage between volume and price of centralized drug procurement, and volume-for-price, other provinces (cities) are now cordially invited to participate in the formation of a provincial cross-regional alliance to carry out centralized procurement of Chinese patent medicines .
-
Baiyunshan's executive deputy general manager Wu Changhai and deputy general manager Zhang Chunbo resigned
Time of Update: 2021-08-28
On the evening of August 16, Baiyunshan issued an announcement stating that the company’s board of directors had received written resignation reports from Executive Deputy General Manager Wu Changhai and Deputy General Manager Zhang Chunbo .
-
Three products of Shuoshi Biotech have been certified by the Saudi Arabian Food and Drug Administration
Time of Update: 2021-08-28
Nucleic acid rapid extraction reagent (magnetic bead method): used to extract and purify viral nucleic acid from serum, plasma, virus culture fluid and other samples; certification number: ME0000001055SFDAA00025; expiration date: August 13, 2021-2024 May 27th3.
-
Up to 800%!
Time of Update: 2021-08-28
According to statistics from the WeChat public account "Yao Chunqiu", 4 nationally sourced varieties entered the ranking of the top 50 domestic annual growth varieties, namely: Engligliflozin tablets, Olanzapine orally disintegrating tablets, and Tofacitib citrate tablets.
Olanzapine orally disintegrating tablets (enter the third batch of national procurement in August 2020)The sales scale has increased from RMB 227.
-
Azivudin, who is in the hands of Roche, talks about the need to circumvent patents in drug development
Time of Update: 2021-08-28
Its structure is shown in the figure below:On November 13, 2007 (at this time, the patent of azvudine compound at Zhengzhou University has not yet been published, and the publication time is May 14, 2008), Roche researchers published the following article in the Journal of Biological Chemistry,This article published the structure and activity data of Azivudine (RO-0622), which is quite amazing.
-
FDA grants emergency use authorization for the third dose of enhanced vaccination of two mRNA new crown vaccines
Time of Update: 2021-08-28
According to the data recently released by Moderna, the results of the phase 2 clinical trial testing the effect of the third dose of the enhanced vaccine showed that the level of neutralizing antibodies against the wild-type new coronavirus remained at 6 months after the second dose of vaccine.
-
Nuocheng Jianhua's new TYK2 inhibitor ICP-332 completes the first subject administration
Time of Update: 2021-08-28
ICP-332 is a class 1 innovative drug with global independent intellectual property rights of Nuocheng Jianhua, and it is a new type of oral TYK2 inhibitor .
-
Sihuan Pharmaceutical's Class 1 new drug CDK4/6 inhibitor approved for Phase III clinical treatment of breast cancer
Time of Update: 2021-08-28
It is also the malignant tumor with the highest incidence of women in the world, and about 680,000 patients died of breast cancer .
-
Yunnan Provincial Food and Drug Administration issued a plan for the promotion of processing Chinese medicinal materials at the origin
Time of Update: 2021-08-28
(4) Based on the idea of fully implementing the main responsibility for quality of pharmaceutical manufacturers, standardize the behavior of Chinese herbal medicine manufacturers in our province to purchase Chinese herbal medicines from the origin (cutting them while they are fresh), including how to extend the quality management system, the demonstration text of the procurement contract and the quality agreement , Regarding how to review the production area processing enterprises, etc.
-
Deck Pharmaceuticals and Shanghai Pharmaceutical Holdings reached a cooperation on the commercialization of Celiniso
Time of Update: 2021-08-28
discussed the import authorization, distribution business, supply chain service and innovation of Celiniso (the special English trade name approved by the US FDA: XPOVIO®, the English common name: selinexor) in China Value-added and other levels reached cooperation intentions and signed agreements .
-
Sartan drugs have been recalled on a large scale due to potential carcinogens!
Time of Update: 2021-08-28
Health Canada reminds patients that the recall of some products may affect the supply of medicines. Patients should be treated according to the doctor's advice. Unless the doctor recommends stopping
-
Heji Pharmaceutical's first ITK inhibitor application IND accepted in the clinical stage in the world
Time of Update: 2021-08-28
On August 17, Heji Pharmaceuticals revealed that its first clinical trial application for the oral ITK inhibitor CPI-818, which entered the clinical development stage, was accepted by the NMPA Drug Approval Center, and it was intended to be used for relapsed/refractory T cells.
-
EQrx and Relay have reached a partnership to develop new anti-tumor drugs with confirmed targets
Time of Update: 2021-08-28
newsnewsOn August 14, the American biotechnology company Relay announced that it will reach a strategic cooperation with me-too master EQrx to develop new anti-tumor drugs with confirmed targets on a global scale when it announced its second quarter report .
-
Allogene's multiple myeloma therapy ALLO-715 won the FDA rare disease drug title
Time of Update: 2021-08-28
ALLO-715 is a CAR-T therapy targeting B cell maturation antigen (BCMA) and a potential new therapy for the treatment of multiple myeloma and other BCMA-positive malignancies .
-
"Guilin Chinese Medicine Resources Code" is issued to promote the sustainable development of Chinese medicine industry
Time of Update: 2021-08-28
Jiang Pinghua said that Guilin is currently actively exploring “to create a suitable technology promotion center for traditional Chinese medicine with strong comprehensive service capabilities, outstanding Chinese medicine characteristics, and obvious specialty advantages, and to explore standard and standardized Chinese medicine diagnosis and treatment models”.
-
The PD-1 inhibitor Daboshu® Phase III clinical study reached the primary endpoint of overall survival
Time of Update: 2021-08-28
The Phase III clinical study (ORIENT-16) is a comparison of Sintilimab or placebo, combined with chemotherapy (oxaliplatin + capecitabine) for the first-line treatment of unresectable locally advanced, recurrent or metastatic A randomized, double-blind, multicenter, phase III study on the effectiveness and safety of adenocarcinoma at the gastroesophageal junction (ClinicalTrials.
